Uncategorized
Glaucoma drug candidate shows low systemic exposure, IOP reduction
Top-line results from a phase 1 pharmacokinetics study showed that a glaucoma drug being developed by Aerie Pharmaceuticals seems to have a low systemic exposure, a high safety profile and an effective IOP-lowering capability, according to a press release.The drug, AR-13324, was administered as an eye drop to 18 healthy subjects once daily for 8 days. Blood levels after administration were at or below the limit of detection at all time points, and no drug-related effects on systemic safety parameters were observed, according to the release.